Tenax Therapeutics (TENX) Price Target Increased by 13.86% to 29.32

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks TENX Tenax Therapeutics (TENX) Price Target Increased by 13.86% to 29.32 March 26, 2026 — 11:14 pm EDT Written by George Maybach for Fintel-> The average one-year price target for Tenax Therapeutics (NasdaqCM:TENX) has been revised to $29.32 / share. This is an increase of 13.86% from the prior estimate of $25.76 dated February 21, 2026. The price target is an average of many targets provided by analysts. The latest targets range from a low of $20.20 to a high of $36.75 / share. The average price target represents an increase of 95.89% from the latest reported closing price of $14.97 / share. What is the Fund Sentiment? There are 54 funds or institutions reporting positions in Tenax Therapeutics. This is an increase of 5 owner(s) or 10.20% in the last quarter. Average portfolio weight of all funds dedicated to TENX is 0.07%, an increase of 31.54%. Total shares owned by institutions increased in the last three months by 39.94% to 6,651K shares. What are Other Shareholders Doing? Ikarian Capital holds 968K shares representing 5.63% ownership of the company. No change in the last quarter. Perceptive Advisors holds 439K shares representing 2.55% ownership of the company. Siren, L.L.C. holds 427K shares representing 2.48% ownership of the company. In its prior filing, the firm reported owning 352K shares , representing an increase of 17.49%. Point72 Asset Management holds 423K shares representing 2.46% ownership of the company. Rtw Investments holds 378K shares representing 2.20% ownership of the company. No change in the last quarter. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.Click to Learn MoreThis story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags Stocks Fintel Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford. Check out our Unique Analysis of Insider Sentiment for Tenax Therapeutics, Inc.-> Find out what the Options Markets think of Tenax Therapeutics, Inc.-> See our take on Tenax Therapeutics, Inc. Upcoming Earnings-> More articles by this source-> Stocks mentioned TENX More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.